Velcade As Front-Line Multiple Myeloma Treatment Solidified By Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Millennium plans to file an sNDA for the indication seeking a priority review by the first quarter of 2008.
You may also be interested in...
ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors
Myeloma trial data released at the American Society of Hematology meeting promises to further lift utilization for Takeda/Millennium's proteasome inhibitor Velcade, which just passed $1 billion in sales
ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors
Myeloma trial data released at the American Society of Hematology meeting promises to further lift utilization for Takeda/Millennium's proteasome inhibitor Velcade, which just passed $1 billion in sales
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.